Historical Controls?

Affiliations

Comment

Paul S Gaynon. Haematologica. 2017 Mar.

. 2017 Mar;102(3):e117.

doi: 10.3324/haematol.2016.159707. Epub 2017 Feb 28.

¹ Children's Center for Cancer and Blood Disease, Children's Hospital Los Angeles, University of Southern California, CA, USA pgaynon@chla.usc.edu.

No abstract available

Comment on

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.
Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, Chia V, Doubek M, Giebel S, Hoelzer D, Ifrah N, Katz A, Kelsh M, Martinelli G, Morgades M, O'Brien S, Rowe JM, Stieglmaier J, Wadleigh M, Kantarjian H. Gökbuget N, et al. Haematologica. 2016 Dec;101(12):1524-1533. doi: 10.3324/haematol.2016.144311. Epub 2016 Sep 1. Haematologica. 2016. PMID: 27587380 Free PMC article.

1. Gökbuget N, Dombret H, Ribera J-M, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016; September 1 [Epub ahead of print] - PMC - PubMed
1. Simon R, Blumenthal GM, Rothenberg ML, et al. The role of nonrandomized trials in the evaluation of oncology drugs. Clin Pharmacol Ther. 2015;97(5):502–507. - PubMed
1. Selaru P, Tang Y, Huang B, et al. Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib. Clin Transl Sci. 2016;9(2):63–73. - PMC - PubMed
1. Vardiman JW, Thiele Je, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. - PubMed
1. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66. - PubMed